TABLE 1.

Clinical trials targeting TLR4 in skin cancer

ClinicalTrials.gov Identifier	Title	Agent	Type	Status
NCT02035657	A proof-of-concept trial of GLA-SE in patients with Merkel cell carcinoma	GLA-SE (TLR4 agonist)	Phase 1	Completed, no results posted
NCT01530698	Single-step antigen loading and TLR activation of dendritic cells in melanoma patients	Autologous dendritic cell vaccine	Interventional, open label	Completed, no results posted
NCT02320305	MART-1 antigen with or without TLR4 agonist GLA-SE in treating patients with stage II-IV melanoma that has been removed by surgery	MART-1 antigen and GLA-SE (TLR4 agonist)	Interventional, open label	Active, not recruiting
NCT03122366	TLR4 polymorphisms and risk of skin cancer	None	Observational	Active, not recruiting

Abbreviations: MART-1, melanoma antigen recognized by T-cells-1; TLR, toll-like receptors.